nach oben

Die Innere Medizin

Erschienen in:

01.10.2006 | Arzneimitteltherapie

Arzneimitteltherapie des Reizdarmsyndroms

Was funktioniert, was nicht – und bei wem?

verfasst von: Prof. Dr. H. Mönnikes, M. Schmidtmann, I. R. van der Voort

Erschienen in: Die Innere Medizin | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie von Reizdarmpatienten ist oft eine Herausforderung, insbesondere wenn ein breites Spektrum von Symptomen vorliegt und anamnestische Hinweise auf Triggerfaktoren, wie diätetische Einflüsse oder Stress, fehlen. Aktuelle pathogenetische Konzepte propagieren Alterationen in ZNS oder Peripherie, die unter Einbeziehung psychologischer (Stress, Angst, Depression) und biologischer Faktoren (postinfektiöse Residuen, subklinische Entzündung) in integrative Krankheitsmodelle eingehen und zur Erklärung nachweisbarer symptomgenerierender Störungen gastrointestinaler Funktionen (Motilität, Hypersensitivität) dienen. Bei fehlenden universal wirksamen oder kausalen Ansätzen orientiert sich die medikamentöse Basistherapie an den führenden Symptomen, insbesondere Schmerz, Diarrhö und Obstipation. Neben etablierten Medikamenten wie Spasmolytika, Opioiden oder Laxantien sind neu entwickelte Substanzen und solche mit primär anderer Indikation (z. B. Antidepressiva) zur differenzierten individuellen Therapie einsetzbar. In Evaluation befindliche, konzeptionell neuartige Ansätze lassen weitere Fortschritte in der Therapie des Reizdarmsyndroms erwarten.

Mönnikes H (1999) Funktionelle gastrointestinale Erkrankungen. In: Göke N, Arnold R (Hrsg) Gastroenterologie systematisch. Uni-Med, Bremen

Drossman DA, Whitehead WE, Camilleri M (1997) Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112: 2120–2137CrossRefPubMed

Thompson WG, Longstreth GF, Drossman DA et al. (1999) Functional bowel disorders and functional abdominal pain. Gut 45 [Suppl 2]: II43–II47PubMed

Mertz HR (2003) Irritable bowel syndrome. N Engl J Med 349: 2136–2146CrossRefPubMed

Andresen V, Bach DR, Poellinger A et al. (2005) Brain activation responses to subliminal or supraliminal rectal stimuli and to auditory stimuli in irritable bowel syndrome. Neurogastroenterol Motil 17: 827–837CrossRefPubMed

Mönnikes H, Tebbe JJ, Hildebrandt M et al. (2001) Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis 19: 201–211CrossRefPubMed

Heymann-Mönnikes I, Arnold R, Florin I et al. (2000) The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 95: 981–994PubMed

Jailwala J, Imperiale TF, Kroenke K (2000) Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 133: 136–147PubMed

Poynard T, Naveau S, Mory B et al. (1994) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 8: 499–510PubMed

10.

Poynard T, Regimbeau C, Benhamou Y (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15: 355–361CrossRefPubMed

11.

Cann PA, Read NW, Holdsworth CD et al. (1984) Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 29: 239–247CrossRefPubMed

12.

Vassallo MJ, Camilleri M, Phillips SF et al. (1992) Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc 67: 725–731PubMed

13.

Efskind PS, Bernklev T, Vatn MH (1996) A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 31: 463–468PubMed

14.

Hovdenak N (1987) Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol [Suppl] 130: 81–84PubMed

15.

Lavo B, Stenstam M, Nielsen AL (1987) Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study. Scand J Gastroenterol [Suppl] 130: 77–80PubMed

16.

Lesbros-Pantoflickova D, Michetti P, Fried M et al. (2004) Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20: 1253–1269CrossRefPubMed

17.

Drossman DA, Camilleri M, Mayer EA et al. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123: 2108–2131CrossRefPubMed

18.

American Gastroenterological Association medical position statement (2002) Irritable bowel syndrome. Gastroenterology 123: 2105–2107CrossRefPubMed

19.

Jackson JL, O’Malley PG, Tomkins G et al. (2000) Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108: 65–72CrossRefPubMed

20.

Brandt LJ, Bjorkman D, Fennerty MB et al. (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97 [11 Suppl]: S7–26PubMed

21.

Quartero AO, Meineche-Schmidt V, Muris J et al. (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (2): CD003460

22.

Gorard DA, Libby GW, Farthing MJ (1994) Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8: 159–166PubMed

23.

Clouse RE, Lustman PJ, Geisman RA et al. (1994) Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 8: 409–416PubMed

24.

Tack J, Broekaert D, Fischler B et al. (2006) A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55: 1095–1103CrossRefPubMed

25.

Vahedi H, Merat S, Rashidioon A et al. (2005) The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 22: 381–385CrossRefPubMed

26.

Tabas G, Beaves M, Wang J et al. (2004) Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 99: 914–920CrossRefPubMed

27.

Creed F, Fernandes L, Guthrie E et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303–317CrossRefPubMed

28.

Crowell MD, Jones MP, Harris LA et al. (2004) Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes. Curr Opin Investig Drugs 5: 736–742PubMed

29.

Pernia A, Mico JA, Calderon E et al. (2000) Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 19: 408–410CrossRefPubMed

30.

Schoenfeld P (2005) Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 34: 319–335, viiiCrossRefPubMed

31.

Talley NJ, Spiller R (2002) Irritable bowel syndrome: a little understood organic bowel disease? Lancet 360: 555–564CrossRefPubMed

32.

Bijkerk CJ, Muris JW, Knottnerus JA et al. (2004) Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 19: 245–251CrossRefPubMed

33.

Hebden JM, Blackshaw E, D’Amato M et al. (2002) Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol 97: 2315–2320CrossRefPubMed

34.

Williams AJ, Merrick MV, Eastwood MA (1991) Idiopathic bile acid malabsorption: a review of clinical presentation, diagnosis, and response to treatment. Gut 32: 1004–1006PubMed

35.

Luman W, Williams AJ, Merrick MV et al. (1995) Idiopathic bile acid malabsorption: long-term outcome. Eur J Gastroenterol Hepatol 7: 641–645PubMed

36.

Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66: 365–378PubMed

37.

Floch MH, Madsen KK, Jenkins DJ et al. (2006) Recommendations for probiotic use. J Clin Gastroenterol 40: 275–278CrossRefPubMed

38.

Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40: 264–269CrossRefPubMed

39.

Malinen E, Rinttila T, Kajander K et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100: 373–382CrossRefPubMed

40.

Chadwick VS, Chen W, Shu D et al. (2002) Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778–1783CrossRefPubMed

41.

O’Mahony L, McCarthy J, Kelly P et al. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541–551CrossRefPubMed

42.

Halpern GM, Prindiville T, Blankenburg M et al. (1996) Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91: 1579–1585PubMed

43.

Niedzielin K, Kordecki H, Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13: 1143–1147CrossRefPubMed

44.

Nobaek S, Johansson ML, Molin G et al. (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95: 1231–1238CrossRefPubMed

45.

Kim HJ, Camilleri M, McKinzie S et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895–904CrossRefPubMed

46.

Hamilton-Miller JMT (2001) Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecology in Health and Disease 13: 212–216CrossRef

47.

Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: 3503–3506CrossRefPubMed

48.

Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412–419PubMed

49.

Hasler WL (2003) Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology 125: 1898–1900CrossRefPubMed

50.

Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314: 779–782PubMed

51.

Barbara G, Stanghellini V, De GR et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126: 693–702CrossRefPubMed

52.

Barbara G, De GR, Deng Y et al. (2001) Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 120: 1729–1736CrossRefPubMed

53.

Dunlop SP, Jenkins D, Neal KR et al. (2003) Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 18: 77–84CrossRefPubMed

54.

Fass R, Fullerton S, Tung S et al. (2000) Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol 95: 1195–2000CrossRefPubMed

55.

Kumar D, Thompson PD, Wingate DL et al. (1992) Abnormal REM sleep in the irritable bowel syndrome. Gastroenterology 103: 12–17PubMed

56.

Orr WC (2000) Sleep and functional bowel disorders: can bad bowels cause bad dreams? Am J Gastroenterol 95: 1118–1121CrossRefPubMed

57.

Goldsmith G, Levin JS (1993) Effect of sleep quality on symptoms of irritable bowel syndrome. Dig Dis Sci 38: 1809–1814CrossRefPubMed

58.

Jarrett M, Heitkemper M, Cain KC et al. (2000) Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Dig Dis Sci 45: 952–959CrossRefPubMed

59.

Roberts-Thomson IC, Knight RE, Kennaway DJ et al. (1988) Circadian rhythms in patients with abdominal pain syndromes. Aust N Z J Med 18: 569–574PubMed

60.

Song GH, Leng PH, Gwee KA et al. (2005) Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 54: 1402–1407CrossRefPubMed

61.

Lu WZ, Gwee KA, Moochhalla S et al. (2005) Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 22: 927–934CrossRefPubMed

62.

Liu JP, Yang M, Liu YX et al. (2006) Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev (1): CD004116

63.

Bensoussan A, Talley NJ, Hing M et al. (1998) Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 280: 1585–1589CrossRefPubMed

64.

Madisch A, Holtmann G, Plein K et al. (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19: 271–279CrossRefPubMed

65.

Sallon S, Ben-Arye E, Davidson R et al. (2002) A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 65: 161–171CrossRefPubMed

66.

Liu W, Weir BS (2004) Affected sib pair tests in inbred populations. Ann Hum Genet 68: 606–619CrossRefPubMed

67.

Grigoleit HG, Grigoleit P (2005) Peppermint oil in irritable bowel syndrome. Phytomedicine 12: 601–606CrossRefPubMed

68.

Pittler MH, Ernst E (1998) Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 93: 1131–1135CrossRefPubMed

69.

Hussain Z, Quigley EM (2006) Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 23: 465–471CrossRefPubMed

70.

Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3 [Suppl 2]: S25–S34

71.

Steadman CJ, Talley NJ, Phillips SF et al. (1992) Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 67: 732–738PubMed

72.

Mearin F (2006) Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Digestion 73 [Suppl 1]: 28–37CrossRefPubMed

73.

Chang L, Ameen VZ, Dukes GE et al. (2005) A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100: 115–123CrossRefPubMed

74.

Cremonini F, Delgado-Aros S, Camilleri M (2003) Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 15: 79–86CrossRefPubMed

75.

Gilkin RJ Jr (2005) The spectrum of irritable bowel syndrome: a clinical review. Clin Ther 27: 1696–1709CrossRefPubMed

76.

Olden KW, Crowell MD (2005) Cilansetron. Drugs Today (Barc) 41: 661–666

77.

Prather CM, Camilleri M, Zinsmeister AR et al. (2000) Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118: 463–468CrossRefPubMed

78.

Kellow J, Lee OY, Chang FY et al. (2003) An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52: 671–676CrossRefPubMed

79.

Chutkan RK (2001) Inflammatory bowel disease. Prim Care 28: 539–556PubMed

80.

Nyhlin H, Bang C, Elsborg L et al. (2004) A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 39: 119–126CrossRefPubMed

81.

Spiller RC (1999) Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 107 (5A): 91S–97SCrossRefPubMed

82.

Evans BW, Clark WK, Moore DJ et al. (2004) Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (1): CD003960

83.

Tougas G, Snape WJ Jr, Otten MH et al. (2002) Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 16: 1701–1708CrossRefPubMed

84.

Fukudo S, Nomura T, Hongo M (1998) Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42: 845–849PubMed

85.

Sagami Y, Shimada Y, Tayama J et al. (2004) Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53: 958–964CrossRefPubMed

86.

Delvaux M, Beck A, Jacob J et al. (2004) Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 20: 237–246CrossRefPubMed

87.

Sanger GJ (2004) Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 141: 1303–1312CrossRefPubMed

88.

Johanson JF, Gargano M, Patchen M et al. (2002) Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation [Abstract]. Gastroenterology 122 [Suppl 1]: A315

89.

Johanson J, Gargano M, Holland PC et al. (2003) Phase III, efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [Abstract]. Gastroenterology 124 [Suppl 1]: A48CrossRef

90.

Johanson J, Gargano MA, Holland PC et al. (2004) Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [Abstract]. Gastroenterology 126 [Suppl 2]: A100

Titel: Arzneimitteltherapie des Reizdarmsyndroms
Was funktioniert, was nicht – und bei wem?
verfasst von: Prof. Dr. H. Mönnikes
M. Schmidtmann
I. R. van der Voort
Publikationsdatum: 01.10.2006
Verlag: Springer-Verlag
Erschienen in: Die Innere Medizin / Ausgabe 10/2006
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-006-1694-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2006

DGIM-Mitteilungen 10/06

Moderne Herzschrittmachertherapie

Herzrhythmusstörungen

Vorhofflimmern

Rezidivierende, stärkste Oberbauchschmerzen bei einem 45-jährigen Patienten